Additionally, downregulation of junB/AP-1 transcription factor recapitulates the clinical aspects of CML [45] and AML [46] and JunB deficiency leads to a CSC-mediated myloproliferative disorder [47, 48]. This evidence concerns the gene JUN and chronic myelogenous leukemia, BCR-ABL1 positive.